I agree that a reverse split is desirable- often in cheap names people get upset over a RS simply because they love owning millions of shares ,but at the end of the day those are not the investors we want looking at this thing- we want larger retail investors and there is a mental leap that is made in terms of credibility once a stock hits a $1 or more. Its not rational, but it nonetheless is true. Even if a 100:1 RS were to be executed, anyone with a decent sized position would still have plenty of shares to diversify if they wanted to take profits and still hold a core position.
I hope you have a day job as well as your predictions of $12 for today and $15 for the week are not quite materializing. One day yes, but not this week. And please, dont be predictable and attack this as soft bashing or supporting Mensa. Its neither
You know it is possible to be long on a position while simultaneously being a little negative on the short term prospects of the name. Thats all he was hinting at- that the name is stuck until the start of the maternal RSV phase trial. "Subtle bashing" is a term for the INO board and retail cheerleaders, grow up
what major event are u referring to that makes the stakes so high over the weekend and leading into monday?
Cohiba- I don' think that we will remain here and generally am happy with the approach of launching phase trials for all 3 indications in the coming months. But as far as 2014 goes thus far- its been a boring year for Nvax aside from our phase trial data that came out in April and very quiet despite a lot of rumors being thrown around regarding Mers, Ebola, and so on. I'm not selling a share, and appreciate your posts- just pointing out that 2014 has been a boring year for the nvax investor as far as pps goes.
the fact that we tanked 50% and have been stuck in a trading range of 4.20- $5 for the remainder of 2014 is a reason to complain
Dr. Kim would have to refrain from buying , even if it were to support the stock price, in the event that a material, nonpublic event such as a partnership was about to be released to the public. The SEC is purposefully vague about what amount of time beforehand one must refrain from acting on material non public information and they do so to keep officers on edge and often the uncertainty causes insiders to air on the side of caution (aka not purchase anywhere near the time a material event is publicly released ).
what you believe is totally incorrect. If you have inside knowledge of material information you cannot purchase stock until the information is brought public.
price action today- when everything is getting crushed, reaffirms our belief that institutions are holding this thing up right now
I am with you on that conclusion- my hunch is that the recent price action is very much institutionally based - not retail. However, there has been some legitimate support on this thing the past 20-30 days and every time it takes a minor hit it bounces back. I am waiting for the secondary offering and will use the over reaction sell off as my entry point to get back in. As you stated- I think the EU approval at a minimum off sets some of the losses if timed with secondary news- or , if released on its own will boost the stock in a major way. Tough call on how to play those cards for mgmt- either way its only PPS and a shorterm problem.
look at the volume -very light. A few late processed orders and perhaps a trade here and there. Ah and Premarket is very irrelevant to the situation- just stay focused on information about the company- not share price. Price swings are going to happen short term- just gotta realize there are different approaches to investing with different time horizons and that people taking profits/ playing short term are in it for different reasons than long term investors. Know your strategy- have a game plan- and stick to it.
Nvax is not going to rise on "potential" for making a quick vaccine on ebola, Mers, or any other articles that people post hoping that the hype will spur a stock rise based on the fact nvax comes up as a number 1 search term on goolge (millennial thought process). Bottom line- when the company starts to make it clear to investors that we can see the finish line on RSV- money will start pouring in. No one cares about potential "pandemic" threats and the lie that the FDA and govt will waive phase trial requirements in a panic to get a vaccine to market.
u post typical small bio unconditional optimism on a regular basis - if thats u want out of people you should start posting on the INO board. This board is fairly objective when compared to other boards- and thats a good thing.
Its not a bad strategy and is what I've been doing also. For a core position- u don't have to be as picky with a buy in price- since in theory u are getting in because u think the company has lots of long term upside. Yeah- u can try to time it perfect- but end of the day if 5-8% is a big deal when all is said and done 3 years from now- the stock will be a disappointment. I do think its important to consider your time horizons and need for cash though- and to have investments that deliver current growth- along with ones that will deliver later on down the road. The day will come for nvax- but its not happening in the next 6 months like many project. Its a 2 year deal.
We haven't had a meaningful event for the company since late april. Need something or we are going to remain stuck. I have been holding two positions- one core and one trading since being a bag holder on this is not an efficient way to make use of your money. Even if we do go to $10 in 2-3 years- you can make more than a 100% in less time than that by actively trading/ while at the same time holding your core to take advantage of tax code and absorb all the gains that accrue over that time.
I don't get what people expect in a penny stock. Its risky and you are going to have huge swings thats a fact. I got in a little high on this, but will hold to see if it plays out. You should never expect a penny stock to blow up- you put it in the portfolio as a potential home run and if it doesn't pan out hey you knew what you got into and you cut your losses. Go to a safe stock with dividends if you don't want the risk- that simple.
thank u vis- bottom line is a lot of ppl preaching partnership right now are short term thinkers that just want another PR- without considering what it means #$%$ away equity). I think INO will make there right choice, but I do not think it is necessarily entering a partnership agreement. Just another buzzword that retail biotech investors use that pray a catalyst will bump up the stock and make them dumb money
I agree with the mentality that trusting in mgmt is key. This is something I did not realize when I first started investing and would overlook. I always cared purely about the name and company fundamentals- and cared less about the leadership style or company officers when it came to shareholders and the company's impression as a whole. Now- I pay a whole lot of attention to it. With small companies like INO that don't have news every day coming out- its critical to have a guy at the helm that knows how the play the PR game, maintain credibility, and execute properly - so that those "drought" periods don't become so concerning from a shareholder's perspective. Gild taught me that first, and INO attracted me initially for the very same reason.